Baxter International INC (BAX) — SEC Filings

Q: What are the key financial highlights for Baxter International INC?

Key financial highlights for Baxter International INC are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Baxter International INC?

Key executives at Baxter International INC are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Baxter International INC stock?

Risk factors for Baxter International INC (BAX) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Baxter International INC?

Forward-looking statements and predictions from Baxter International INC are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Baxter International INC. Recent 8-K filing on Dec 22, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Baxter International INC on SEC EDGAR

Overview

Baxter International INC (BAX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 12, 2025: Baxter International Inc. announced on November 5, 2025, changes in its board of directors and executive compensation. Specifically, the company reported the departure of certain directors and officers, the election of new directors, and adjustments to the compensatory arrangements for its named exe

Sentiment Summary

Across 47 filings, the sentiment breakdown is: 1 bearish, 45 neutral, 1 mixed. The dominant filing sentiment for Baxter International INC is neutral.

Filing Type Overview

Baxter International INC (BAX) has filed 30 8-K, 6 10-Q, 2 DEF 14A, 2 DEFA14A, 2 10-K, 1 8-K/A, 3 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (47)

8-K Filing — 8-K · Dec 22, 2025
8-K Filing — 8-K · Dec 4, 2025
8-K Filing — 8-K · Nov 25, 2025
8-K Filing — 8-K · Nov 19, 2025
Baxter International Inc. Reports Board and Executive Compensation Changes — 8-K · Nov 12, 2025 Risk: medium
Baxter International Inc. announced on November 5, 2025, changes in its board of directors and executive compensation. Specifically, the company reported the de
Baxter Swings to Q3 Loss Amid Kidney Care Divestiture Adjustments — 10-Q · Nov 4, 2025 Risk: medium
Baxter International Inc. reported a net loss attributable to stockholders of $46 million for the three months ended September 30, 2025, a significant decline f
Baxter International Inc. Files 8-K on Financials — 8-K · Oct 30, 2025 Risk: low
Baxter International Inc. filed an 8-K on October 30, 2025, reporting on its results of operations and financial condition, and filing financial statements and
Baxter International Inc. Reports Board and Executive Compensation Changes — 8-K · Oct 21, 2025 Risk: low
Baxter International Inc. announced on October 16, 2025, changes in its board of directors and executive compensation. Specifically, the company reported the de
Baxter Swings to $1.05B Loss on BioPharma Unit Impairment — 10-Q · Aug 5, 2025 Risk: high
Baxter International Inc. reported a net loss of $1.049 billion for the six months ended June 30, 2025, a significant decline from a net income of $345 million
Baxter International Inc. Files 8-K on Financials — 8-K · Jul 31, 2025 Risk: low
Baxter International Inc. filed an 8-K on July 31, 2025, reporting on its results of operations and financial condition. The filing includes financial statement
Baxter International Inc. Files 8-K: Board & Officer Changes — 8-K · Jul 7, 2025 Risk: low
On July 7, 2025, Baxter International Inc. filed an 8-K report detailing changes in its board of directors and certain officers, along with updates on compensat
Baxter International Inc. Enters New Agreements, Terminates Others — 8-K · Jun 12, 2025 Risk: medium
On June 11, 2025, Baxter International Inc. entered into a material definitive agreement and simultaneously terminated another. The company also created a direc
Baxter International Inc. Files 8-K on Shareholder Matters — 8-K · May 8, 2025 Risk: low
Baxter International Inc. filed an 8-K on May 8, 2025, reporting on matters submitted to a vote of security holders on May 6, 2025. The filing details the compa
Baxter International Inc. Files 10-Q for Q1 2025 — 10-Q · May 6, 2025 Risk: low
Baxter International Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's filing details its financial position and operational hi
Baxter International Inc. Files 8-K on Financials — 8-K · May 1, 2025 Risk: low
Baxter International Inc. filed an 8-K on May 1, 2025, reporting on its results of operations and financial condition, and including financial statements and ex
Baxter International Inc. DEF 14A Filing — DEF 14A · Mar 25, 2025 Risk: low
Baxter International Inc. filed its DEF 14A on March 25, 2025, detailing executive compensation and corporate governance for the fiscal year ending December 31,
Baxter International Inc. Files Proxy Materials — DEFA14A · Mar 25, 2025 Risk: low
Baxter International Inc. filed a Definitive Additional Materials proxy statement on March 25, 2025. This filing relates to the company's proxy statement, which
Baxter International Inc. Files 8-K — 8-K · Mar 14, 2025 Risk: low
Baxter International Inc. filed an 8-K on March 14, 2025, reporting on Regulation FD disclosures and financial statements. The filing includes details about the
Baxter International Files 2024 10-K — 10-K · Feb 21, 2025 Risk: medium
Baxter International Inc. filed its 2024 10-K on February 21, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered in Deerfie
Baxter International Inc. Files 8-K on Financials — 8-K · Feb 20, 2025 Risk: low
Baxter International Inc. filed an 8-K on February 20, 2025, reporting on its results of operations and financial condition, and including financial statements
Baxter International Files 8-K/A Amendment — 8-K/A · Feb 6, 2025 Risk: low
Baxter International Inc. filed an amendment (8-K/A) on February 6, 2025, related to events reported as of January 31, 2025. This filing primarily concerns Regu
Baxter CFO Departs, Interim Appointed — 8-K · Feb 3, 2025 Risk: medium
Baxter International Inc. announced the departure of its Chief Financial Officer, Joel A. Dragon, effective January 31, 2025. The company also appointed Shannon
Baxter International Adds Two New Directors — 8-K · Feb 3, 2025 Risk: low
Baxter International Inc. announced on February 3, 2025, that its Board of Directors has elected two new directors, Amy E. Miles and David L. Schlotterbeck, eff
Baxter International Inc. Announces Executive and Board Changes — 8-K · Jan 31, 2025 Risk: medium
Baxter International Inc. announced on January 31, 2025, changes in its executive team and board of directors. The filing details the departure of certain offic
Baxter International Inc. Files 8-K — 8-K · Nov 27, 2024 Risk: low
Baxter International Inc. filed an 8-K on November 26, 2024, reporting amendments to its articles of incorporation or bylaws and filing financial statements and
Baxter Appoints New Chief Medical and Scientific Officers — 8-K · Nov 22, 2024 Risk: low
Baxter International Inc. announced on November 18, 2024, changes in its executive leadership. The company appointed Dr. John T. "Jay" Davies as Chief Medical O
SC 13G/A Filing — SC 13G/A · Nov 13, 2024
Baxter International Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 12, 2024 Risk: low
Baxter International Inc. reported its third-quarter results for the period ending September 30, 2024. The company's financial performance for the quarter and y
Baxter International Inc. Files 8-K on Financials — 8-K · Nov 8, 2024 Risk: low
Baxter International Inc. filed an 8-K on November 8, 2024, reporting on its results of operations and financial condition, as well as filing financial statemen
Baxter International Inc. Files 8-K — 8-K · Nov 7, 2024 Risk: low
Baxter International Inc. filed an 8-K on November 7, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
Baxter International Inc. Files 8-K for Regulation FD Disclosure — 8-K · Oct 9, 2024 Risk: low
Baxter International Inc. announced on October 8, 2024, that it is providing a Regulation FD Disclosure. The filing does not contain specific details about the
Baxter International Inc. Files 8-K — 8-K · Sep 30, 2024 Risk: low
Baxter International Inc. filed an 8-K on September 30, 2024, reporting events as of September 29, 2024. The filing is a current report under Regulation FD and
Baxter International Inc. Reports Board and Officer Changes — 8-K · Sep 9, 2024 Risk: medium
Baxter International Inc. announced on September 9, 2024, a change in its board of directors. Specifically, the company reported the departure of certain office
Baxter International Inc. Announces Executive and Board Changes — 8-K · Sep 3, 2024 Risk: medium
Baxter International Inc. announced on September 3, 2024, changes in its executive team and board of directors. The filing details the departure of certain offi
Baxter International Prices $1.75 Billion Senior Notes Offering — 8-K · Aug 13, 2024 Risk: medium
Baxter International Inc. announced on August 12, 2024, the entry into a material definitive agreement related to its senior unsecured notes. The company is iss
Baxter International Inc. Files 10-Q for Q2 2024 — 10-Q · Aug 6, 2024 Risk: low
Baxter International Inc. reported its second quarter 2024 results, ending June 30, 2024. The company's financial performance for the period and its ongoing ope
Baxter International Inc. Issues New Senior Unsecured Notes — 8-K · Jul 18, 2024 Risk: medium
On July 17, 2024, Baxter International Inc. entered into a material definitive agreement related to the issuance of senior unsecured notes. This agreement invol
Baxter International Inc. Files 8-K on Director Changes and Compensation — 8-K · May 9, 2024 Risk: low
Baxter International Inc. filed an 8-K on May 9, 2024, reporting on several key events including the departure of a director, election of a new director, and am
Baxter International Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 2, 2024 Risk: low
BAXTER INTERNATIONAL INC (BAX) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Baxter International Inc. filed its quarterly report (10-Q) for the
Baxter International Inc. Files Definitive Proxy Materials — DEFA14A · Mar 27, 2024 Risk: low
Baxter International Inc. filed a Definitive Additional Materials proxy statement on March 27, 2024. This filing relates to the company's annual meeting and is
Baxter International Inc. Files Definitive Proxy Statement — DEF 14A · Mar 25, 2024 Risk: low
BAXTER INTERNATIONAL INC (BAX) filed a Proxy Statement (DEF 14A) with the SEC on March 25, 2024. Baxter International Inc. filed a Definitive Proxy Statement (D
Baxter International Inc. Files 8-K for Material Agreement — 8-K · Mar 21, 2024 Risk: medium
On March 21, 2024, Baxter International Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and ex
Baxter International Inc. Files 8-K for Regulation FD Disclosure — 8-K · Mar 4, 2024 Risk: low
On March 4, 2024, Baxter International Inc. filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure, indicating that th
SC 13G Filing — SC 13G · Feb 13, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
Baxter International Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 8, 2024 Risk: medium
BAXTER INTERNATIONAL INC (BAX) filed a Annual Report (10-K) with the SEC on February 8, 2024. Baxter International Inc. filed its 2023 Form 10-K on February 8,
BlackRock Amends Baxter International Stake (SC 13G/A) — SC 13G/A · Jan 23, 2024
BlackRock Inc. filed an amended Schedule 13G/A on January 23, 2024, indicating a change in its ownership of Baxter International Inc. common stock as of Decembe

Risk Profile

Risk Assessment: Of BAX's 39 recent filings, 1 were flagged as high-risk, 12 as medium-risk, and 26 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Baxter International INC's most recent 10-Q filing (Nov 4, 2025):

Revenue: $2.835B
Net Income: $(46)M
EPS: $(0.09)
Debt-to-Equity: 1.91
Cash Position: $1.726B
Operating Margin: 6.1%
Total Assets: $21.067B
Total Debt: $9.500B

Key Executives

Joel A. Dragon
Shannon M. Daffron
Amy E. Miles
David L. Schlotterbeck
Dr. John T. "Jay" Davies
Dr. Laura J. V. Johnson

Industry Context

Baxter International operates in the highly competitive medical products and healthcare industry, facing global players in areas like renal care, medical devices, and pharmaceuticals. Key trends include increasing demand for innovative medical technologies, a focus on cost containment by healthcare systems, and evolving regulatory landscapes worldwide. The company's strategic divestitures, such as the Kidney Care business, indicate a focus on optimizing its portfolio for future growth areas.

Top Tags

executive-compensation (6) · financial-reporting (6) · 8-k (5) · sec-filing (5) · disclosure (5) · governance (4) · corporate-governance (4) · 10-Q (4) · Medical Devices (3) · debt (3)

Key Numbers

Net Sales: $2.835B — Increased from $2.699B in Q3 2024, a 5% increase.
Net Income (Loss) Attributable to Baxter Stockholders: $(46)M — Swung from a $140M income in Q3 2024 to a loss in Q3 2025.
Basic Income (Loss) Per Common Share: $(0.09) — Decreased from $0.27 in Q3 2024.
Kidney Care Business Sale Price: $3.80B — Aggregate cash purchase price received from Carlyle.
Pre-tax Gain on Sale of Kidney Care Business: $115M — Recognized for the nine months ended September 30, 2025, before Q3 adjustments.
Reduction in Gain on Sale: $55M — Pre-tax reduction in Q3 2025 due to final working capital adjustments.
Hurricane Helene Related Charges: $123M — Pre-tax net charges for the nine months ended September 30, 2025.
Cash and Cash Equivalents: $1.726B — As of September 30, 2025, down from $1.764B at December 31, 2024.
Long-term Debt: $8.747B — As of September 30, 2025, reduced from $10.374B at December 31, 2024.
Common Stock Shares Outstanding: 514,055,805 — As of October 31, 2025.
Net Loss: $1.049B — For the six months ended June 30, 2025, a significant swing from $345M net income in 2024.
Impairment Charge: $1.3B — Pre-tax charge related to the BioPharma Solutions reporting unit in Q2 2025.
Revenue: $5.9B — For the six months ended June 30, 2025, a slight decrease from $6.0B in 2024.
FX Impact: 1% — Negative impact on sales in Q2 2025 due to foreign currency exchange rates.
Reporting Period End: 20250331 — End of the first quarter of 2025

Forward-Looking Statements

{"claim":"Baxter will continue to focus on its core 'Surgical & Medical Instruments & Apparatus' business.","entity":"BAXTER INTERNATIONAL INC","targetDate":"2024-12-31","confidence":"high"}
{"claim":"The company's financial performance will be closely scrutinized by investors following this detailed 10-K.","entity":"BAXTER INTERNATIONAL INC","targetDate":"2024-03-31","confidence":"medium"}

Related Companies

CG · MDT · ABT

Frequently Asked Questions

What are the latest SEC filings for Baxter International INC (BAX)?

Baxter International INC has 47 recent SEC filings from Jan 2024 to Dec 2025, including 30 8-K, 6 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of BAX filings?

Across 47 filings, the sentiment breakdown is: 1 bearish, 45 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Baxter International INC SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Baxter International INC (BAX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Baxter International INC?

Key financial highlights from Baxter International INC's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for BAX?

The investment thesis for BAX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Baxter International INC?

Key executives identified across Baxter International INC's filings include Joel A. Dragon, Shannon M. Daffron, Amy E. Miles, David L. Schlotterbeck, Dr. John T. "Jay" Davies and 1 others.

What are the main risk factors for Baxter International INC stock?

Of BAX's 39 assessed filings, 1 were flagged high-risk, 12 medium-risk, and 26 low-risk.

What are recent predictions and forward guidance from Baxter International INC?

Recent forward-looking statements from Baxter International INC include guidance on {"claim":"Baxter will continue to focus on its core 'Surgical & Medical Instruments & Apparatus' business.","entity":"BA and 1 other predictions.